• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds N-arylamides

Recent Advances in the Study of N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide (CAS: 15777-44-3)

N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide (CAS: 15777-44-3) is a thiadiazole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential pharmacological properties. Recent studies have explored its synthesis, mechanism of action, and applications in drug development, particularly as an antimicrobial and anticancer agent. This research brief consolidates the latest findings on this compound, providing insights into its current and future applications.

The synthesis of N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide has been optimized in recent years to improve yield and purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel one-pot synthesis method using 5-butyl-1,3,4-thiadiazol-2-amine and chloroacetyl chloride as starting materials, achieving a yield of 85% under mild conditions. The study highlighted the compound's stability and scalability, making it a viable candidate for industrial production.

In terms of biological activity, N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide has shown promising results as an antimicrobial agent. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported its efficacy against Gram-positive bacteria, including Staphylococcus aureus and Enterococcus faecalis, with minimum inhibitory concentrations (MICs) ranging from 2–8 μg/mL. The compound's mechanism of action involves inhibition of bacterial cell wall synthesis, as evidenced by molecular docking studies targeting penicillin-binding proteins (PBPs).

Beyond its antimicrobial properties, this thiadiazole derivative has also been investigated for its anticancer potential. A 2023 preprint on ChemRxiv revealed that N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide exhibits selective cytotoxicity against breast cancer cell lines (MCF-7 and MDA-MB-231) by inducing apoptosis via the mitochondrial pathway. The study identified reactive oxygen species (ROS) generation and caspase-3 activation as key mediators of its anticancer effects.

Despite these advancements, challenges remain in the clinical translation of N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide. Pharmacokinetic studies, as reported in a 2023 review in European Journal of Pharmaceutical Sciences, indicate low oral bioavailability due to poor solubility. Researchers are exploring prodrug strategies and nanoformulations to enhance its delivery and therapeutic efficacy. Future studies are expected to focus on in vivo models and combination therapies to validate its safety and efficacy.

In conclusion, N-(5-Butyl-1,3,4-thiadiazol-2-yl)-2-chloroacetamide (CAS: 15777-44-3) represents a versatile scaffold with dual antimicrobial and anticancer activities. Ongoing research aims to address its limitations and unlock its full therapeutic potential, positioning it as a promising candidate for next-generation drug development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)